An FDA Panel Just Endorsed These Unproven Peptides
An FDA advisory panel narrowly recommended allowing compounding pharmacies to make four unapproved peptides, despite FDA scientists advising against their use because safety and effectiveness evidence is limited. The recommendation could bring some widely marketed “wellness” and injury-recovery treatments closer to regulated prescription access, but it does not amount to FDA approval and has prompted concern that patients may misunderstand the level of evidence behind them.
The committee voted 8–6, with one abstention, to add BPC-157, KPV and TB-500 to the FDA’s bulks list; MOTs-C received a 7–5 vote, with two abstentions. BPC-157 and TB-500 are promoted online as a “Wolverine stack” for recovery, while peptide advocates argued regulated compounding could reduce reliance on potentially contaminated grey-market products; critics said it could instead lend unproven treatments unwarranted legitimacy. The panel, some of whose members have links to peptide businesses or telehealth clinics, was due to consider three further peptides.
In short
- FDA panel backs compounding access for four unproven peptides.
- FDA scientists said safety and effectiveness evidence remains insufficient.
- Recommendation is not the same as FDA approval.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Supporters argue that these peptides are already widely available in unregulated grey-market channels, often contaminated or of unknown composition. Rather than prohibiting their use—which has failed to stop demand—allowing regulated compounding could harness the safety benefits of pharmaceutical oversight: verified ingredients, proper manufacturing standards, and documented batches. They contend that moving these treatments from shadow markets into supervised pharmacies represents practical harm reduction, and that patients already using these compounds deserve access to versions produced under quality control, regardless of whether clinical evidence remains limited.
The case against
Critics maintain that approving compounding of unproven treatments violates fundamental principles of evidence-based medicine and patient protection. They argue the narrow committee vote reflects genuine scientific disagreement about safety and efficacy, compounded by conflicts of interest among panel members. They worry that allowing regulated compounding will lend these substances unwarranted legitimacy, potentially encouraging patients to prioritise unproven peptides over established treatments, whilst creating commercial pressure to expand use without adequate safety data. Protecting public health, they contend, sometimes requires restraint even when demand exists.
Explained simply
Peptides are substances used in some wellness and injury-recovery treatments, and four of them are being considered for legal production by compounding pharmacies under FDA oversight. An advisory panel has narrowly recommended approving their use in this way. However, the FDA's own scientists have stated there is insufficient evidence that these treatments are safe and effective.
These peptides, particularly BPC-157 and TB-500, are currently sold online and marketed to people seeking recovery from injuries or improved athletic performance, though they are not formally approved for any medical use. The advisory panel's vote was close, and some panel members have financial connections to companies that sell or promote these treatments or related businesses. The panel's recommendation does not amount to full FDA approval.
The distinction matters because patients might assume that the panel's endorsement means these treatments have been thoroughly tested and proven safe, which is not necessarily the case. Supporters of the recommendation argue that bringing these substances under pharmacy regulation could prevent people from buying potentially contaminated or mislabelled versions from unregulated sources. Opponents worry that regulatory oversight could instead give false legitimacy to unproven treatments.